Skip to main content
. Author manuscript; available in PMC: 2022 May 3.
Published in final edited form as: Clin Cancer Res. 2021 Jan 7;27(6):1695–1705. doi: 10.1158/1078-0432.CCR-20-4073

Figure 2.

Figure 2

A. Tumor mutational burden (TMB), homopolymer indel (HPI) frequency and base change spectrum in our identified groups: MMR-D: BRAF V600E mutated, Lynch syndrome and RTK fusions. MSS: RTK fusions and RSPO fusion. All three MMR-D subgroups have a higher TMB and HPI than MSS tumors with RTK or RSPO fusions. B. Lynch syndrome tumors demonstrate a higher TMB and HPI than MMR-D BRAF V600E tumors. Median TMB and HPI levels of MMR-D RTK fusion tumors are closer to MMR-D BRAF V600E tumors (text) but not significantly (ns) different from Lynch syndrome tumors, probably because of low case numbers. C. Co-mutation plot for the pre-defined groups. D. Varying frequencies of various oncogenes among the three MMR-D cancer subgroups. Q values for each oncogene are listed beneath their identifiers. Oncogenic mutations in KRAS, ERBB2 and CTNNB1 show relative predominance in Lynch syndrome. E. Lynch syndrome-associated MMR-D cancers demonstrate a lower median contribution from signature 15 than do BRAF V600E and RTK fusion-associated MMR-D cancers.